BH akademski imenik

T. Straatmijer, Fiona D M van Schaik, A. Bodelier, M. Visschedijk, A. D. de Vries, C. Ponsioen, M. Pierik, A. V. van Bodegraven, R. West, N. D. de Boer, N. Srivastava, T. Romkens, J. Hoekstra, B. Oldenburg, G. Dijkstra, J. C. van der Woude, M. Löwenberg, Z. Mujagic, V. Biemans, A. van der Meulen-de Jong, M. Duijvestein

13 25. 10. 2022.

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

Alimentary Pharmacology and Therapeutics

Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment.

Preuzmi PDF

Medicine
+ 1

Pretplatite se na novosti o BH Akademskom Imeniku